LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 95

Search options

  1. Article: COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2021  Volume 14, Issue 7

    Abstract: The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the ... ...

    Abstract The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon β-1a; remdesivir. The trial was discontinued due to the lack of positive results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small molecules, antibodies, and stem cells.
    Language English
    Publishing date 2021-07-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph14070664
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: 2019: An Awesome Year for

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2020  Volume 13, Issue 1

    Abstract: Ending the year is an opportunity to reflect on the past, in particular the past twelve months [ ... ]. ...

    Abstract Ending the year is an opportunity to reflect on the past, in particular the past twelve months [...].
    Language English
    Publishing date 2020-01-01
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph13010006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Repositioning Oxybutynin Hydrochloride

    Jean Jacques Vanden Eynde

    Drugs and Drug Candidates, Vol 2, Iss 4, Pp 865-

    State of the Art in Synthesis, Mode of Action, Metabolism, and Formulations

    2023  Volume 882

    Abstract: For decades, oxybutynin hydrochloride has been prescribed to improve bladder control in cases of incontinence and excessive urination frequency. This review summarizes synthetic methods enabling the preparation of the racemic drug and, in a detailed ... ...

    Abstract For decades, oxybutynin hydrochloride has been prescribed to improve bladder control in cases of incontinence and excessive urination frequency. This review summarizes synthetic methods enabling the preparation of the racemic drug and, in a detailed manner, preparation of ( S )-2-cyclohexyl-2-hydroxy-2-phenylacetic acid, a key intermediate in the synthesis of ( S )-oxybutynin. The mode of action and metabolism are briefly addressed in order to explain the main adverse effects associated with its use and to justify the evolution observed in the diverse commercial formulations. Repositioning opportunities are discussed in terms of clinical trials for the management of hyperhidrosis, hot flashes, and obstructive sleep apnea.
    Keywords bladder ; breast cancer ; hot flashes ; hyperhidrosis ; obstructive sleep apnea ; oxybutynin ; Pharmacy and materia medica ; RS1-441 ; Chemistry ; QD1-999
    Language English
    Publishing date 2023-10-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article: COVID-19: A Brief Overview of the Discovery Clinical Trial.

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2020  Volume 13, Issue 4

    Abstract: The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and ... ...

    Abstract The outbreak of COVID-19 is leading to a tremendous search for curative treatments. The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.
    Keywords covid19
    Language English
    Publishing date 2020-04-10
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph13040065
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: COVID-19: An Update About the Discovery Clinical Trial.

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2020  Volume 13, Issue 5

    Abstract: Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic. Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules ... ...

    Abstract Finding efficacious and safe treatments for COVID-19 emerges as a crucial need in order to control the spread of the pandemic. Whereas plasma therapy attracts much interest, the European project Discovery focuses on the potentialities of small molecules like remdesivir, the combination of lopinavir/ritonavir, hydroxychloroquine, and chloroquine. Results recently published on the clinical evaluation of those drugs are compiled in this brief report, although complete data are still impatiently awaited.
    Keywords covid19
    Language English
    Publishing date 2020-05-14
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph13050098
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Pharmaceuticals: Impact Factor or CiteScore™.

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2017  Volume 10, Issue 3

    Abstract: n/a. ...

    Abstract n/a.
    Language English
    Publishing date 2017-07-06
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph10030061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: 2017: A Fruitful Year for Pharmaceuticals.

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2017  Volume 11, Issue 1

    Abstract: First of all, let me wish you a healthy and wonderful year in 2018 [ ... ]. ...

    Abstract First of all, let me wish you a healthy and wonderful year in 2018 [...].
    Language English
    Publishing date 2017-12-21
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph11010001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: COVID-19

    Jean Jacques Vanden Eynde

    Pharmaceuticals, Vol 14, Iss 664, p

    Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?

    2021  Volume 664

    Abstract: The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the ... ...

    Abstract The DisCoVeRy clinical trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon β-1a; remdesivir. The trial was discontinued due to the lack of positive results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small molecules, antibodies, and stem cells.
    Keywords antibodies ; COVID-19 ; cytokine storm ; hydroxychloroquine ; lopinavir ; remdisivir ; Medicine ; R ; Pharmacy and materia medica ; RS1-441
    Language English
    Publishing date 2021-07-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article: Progress Confirmed for Pharmaceuticals in 2016.

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2016  Volume 10, Issue 1

    Abstract: n/a. ...

    Abstract n/a.
    Language English
    Publishing date 2016-12-26
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph10010001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

    Vanden Eynde, Jean Jacques

    Pharmaceuticals (Basel, Switzerland)

    2017  Volume 10, Issue 2

    Abstract: Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry. ...

    Abstract Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.
    Language English
    Publishing date 2017-05-22
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph10020048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top